Retatrutide
A first-in-class triple receptor agonist simultaneously activating GLP-1, GIP, and glucagon receptors to regulate appetite, insulin sensitivity, and thermogenesis — addressing the metabolic dysregulation behind obesity at its root.
A first-in-class triple receptor agonist simultaneously activating GLP-1, GIP, and glucagon receptors to regulate appetite, insulin sensitivity, and thermogenesis — addressing the metabolic dysregulation behind obesity at its root.
Retatrutide engages three complementary receptor pathways: GLP-1R suppresses appetite and slows gastric emptying; GIPR enhances insulin sensitivity and modulates adipose tissue; glucagon receptor increases hepatic glucose output and thermogenesis. This tri-receptor agonism creates synergistic and sustained reductions in body weight, visceral fat, and cardiometabolic risk markers beyond what single-target approaches achieve.
- [1]Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389(6):514-526.
- [2]Coskun T, et al. (2022). LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist. Molecular Metabolism, 63:101545.
- [3]Samms RJ, et al. (2023). Emerging role of GIP in the pathophysiology of obesity and its therapeutic implications. Cell Reports Medicine, 4(3):100934.
Educational Content Only. This information is provided for research awareness and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any health decisions.